Medicenna Therapeutics (TSE:MDNA) Hits New 52-Week Low – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) hit a new 52-week low on Tuesday . The company traded as low as C$0.42 and last traded at C$0.43, with a volume of 46475 shares traded. The stock had previously closed at C$0.43.

Medicenna Therapeutics Trading Up 1.2%

The business has a 50-day simple moving average of C$0.58 and a two-hundred day simple moving average of C$0.88. The stock has a market cap of C$35.87 million, a price-to-earnings ratio of -2.87 and a beta of 2.90. The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65.

Medicenna Therapeutics (TSE:MDNA) last issued its earnings results on Thursday, April 30th. The company reported C($0.06) earnings per share for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. Equities analysts forecast that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.